Compare Apollo Global Management Ord Shs (APO) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apollo Global Management Ord Shs vs Quest Diagnostics Inc — how do they compare? Apollo Global Management Ord Shs trades at $137.72 (market cap $82.84B), while Quest Diagnostics Inc trades at $238.01 (market cap $26.21B). The key difference: Apollo Global Management Ord Shs is far larger — about 3.2× Quest Diagnostics Inc's market cap, and Apollo Global Management Ord Shs pays the higher dividend (1.6%). Which is the better fit depends on your goals.
| APO | DGX | |
|---|---|---|
Market Cap | $82.84B | $26.21B |
Sector | Financials | Health |
52-Week High | $152.70 | $238.50 |
52-Week Low | $100.30 | $173.49 |
Enterprise Value | -$168.65B | $31.97B |
Dividend Yield | 1.6% | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Apollo Global Management (APO) trades at $132.02, up 3.59% in 24 hours, with strong technical momentum as it approaches resistance near $134. The company reported mixed Q2 2026 earnings, missing EPS estimates but achieving record fee-related earnings of $785 million (Seeking Alpha, August 4, 2026). Fundamentals show robust revenue growth, with 2025 revenue at $32.05 billion, though net income margins have declined to 5.22% from prior peaks.
Outlook remains positive with an 82% analyst buy rating and a $151.50 price target, but risks include high P/E of 49.92 and exposure to private credit market volatility. Recent news highlights strategic AI infrastructure deals, such as a $2.6 billion partnership with Yankee Global Enterprises (Business Wire, August 11, 2026), supporting long-term growth amid competitive pressures.
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
